<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Prime</title>
	<atom:link href="http://www.tapanray.in/tag/prime/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Uniting Pharma With Business Ethics: A Bridge Too Far?</title>
		<link>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=uniting-pharma-with-business-ethics-a-bridge-too-far</link>
		<comments>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/#comments</comments>
		<pubDate>Mon, 18 Feb 2019 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[promotional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reminders]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uniting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9414</guid>
		<description><![CDATA[Operating ethically not only is the right thing to do but also is fundamental to success in business. Poor governance and poor ethical business practices can lead to fines, public scrutiny and distrust – overshadowing good performance, destroying reputation, and &#8230; <a href="http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patients’ Trust And Pharma Remain Strange Bedfellows?</title>
		<link>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patients-trust-and-pharma-remain-strange-bedfellows</link>
		<comments>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/#comments</comments>
		<pubDate>Mon, 03 Sep 2018 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bedfellows]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[strange]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uneasy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9129</guid>
		<description><![CDATA[Like many other industries, pharmaceutical companies too often talk about improving focus on effective ‘stakeholder-relationship management’. The doctors obviously form an integral part of this process. There is nothing wrong with it. Nevertheless, serious concern of ‘conflict of interest’ between &#8230; <a href="http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patients-trust-and-pharma-remain-strange-bedfellows/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Draft Pharma Policy 2017 And Branded Generics</title>
		<link>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=draft-pharma-policy-2017-and-branded-generics</link>
		<comments>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/#comments</comments>
		<pubDate>Sun, 27 Aug 2017 23:55:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GLP]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unbranded]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WOW]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8385</guid>
		<description><![CDATA[In its first reading, the 18-page draft Pharma Policy, 2017 gives me a sense that the Government has followed the much-desired principle of ‘walk the talk’, especially in some key areas. One such space is what Prime Minister Modi distinctly &#8230; <a href="http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Department of Pharmaceuticals On The Same Page As The Prime Minister?</title>
		<link>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister</link>
		<comments>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/#comments</comments>
		<pubDate>Sun, 14 May 2017 23:56:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMC]]></category>
		<category><![CDATA[amended]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[malevolent]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[statute]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unholy]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8225</guid>
		<description><![CDATA[“The open secret is that pharmaceutical companies throw all manners of inducements on doctors to prescribe their medicines. The victim of their misdemeanors is the unsuspecting patient. Mr. Modi clearly wants to break this self-serving chain” – highlighted a media &#8230; <a href="http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-department-of-pharmaceuticals-on-the-same-page-as-the-prime-minister/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescriptions in Generic Names Be Made A Must in India?</title>
		<link>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescriptions-in-generic-names-be-made-a-must-in-india</link>
		<comments>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/#comments</comments>
		<pubDate>Mon, 24 Apr 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aaadhar]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[identification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMJAY]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Surat]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8196</guid>
		<description><![CDATA[Would prescriptions in generic names be made a must in India? Yes, that’s what Prime Minister Modi distinctly hinted at on April 17, 2017, during the inauguration function of a charitable hospital in Surat. To facilitate this process, his government &#8230; <a href="http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Indian Drug Control World’s Weakest: Pharma Trade Bodies Working At Cross Purposes&#8217;</title>
		<link>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes</link>
		<comments>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/#comments</comments>
		<pubDate>Mon, 25 Apr 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[cross-purposes]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Edmund]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safra]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7612</guid>
		<description><![CDATA[&#8220;In the entire world, I think our drug control system probably is the weakest today. It needs to be strengthened,&#8221; said the Secretary of the Department of Pharmaceuticals (DoP) &#8211; V K Subburaj at an event in New-Delhi on April &#8230; <a href="http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-drug-control-worlds-weakest-pharma-trade-bodies-working-at-cross-purposes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Worsening Health Effect Of Climate Change In India: A Perspective</title>
		<link>http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=worsening-health-effect-of-climate-change-in-india-a-perspective</link>
		<comments>http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/#comments</comments>
		<pubDate>Mon, 14 Dec 2015 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Chennai]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[earth]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[extinction]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[NASA]]></category>
		<category><![CDATA[Paris]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[planet]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Race]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[worsening]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7333</guid>
		<description><![CDATA[At present, out of the top five most pressing global and local environmental challenges, ‘Climate Change’ features at the top. It has been broadly defined as, “a change in global or regional climate patterns, in particular a change apparent from &#8230; <a href="http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Heath Care: My Expectations From The Union Budget (2016-17)</title>
		<link>http://www.tapanray.in/heath-care-my-expectations-from-the-union-budget-2016-17/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=heath-care-my-expectations-from-the-union-budget-2016-17</link>
		<comments>http://www.tapanray.in/heath-care-my-expectations-from-the-union-budget-2016-17/#comments</comments>
		<pubDate>Mon, 07 Dec 2015 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016-17]]></category>
		<category><![CDATA[constiturion]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lok]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Narendra]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pre-budget]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Right to life]]></category>
		<category><![CDATA[Sabha]]></category>
		<category><![CDATA[speech]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7315</guid>
		<description><![CDATA[India Celebrated its ‘Constitution Day’ on November 26 this year, as the Constitution of the country was adopted by the Constituent Assembly on November 26, 1949, which came into force on January 26,1950.  On November 27, 2015, while addressing the &#8230; <a href="http://www.tapanray.in/heath-care-my-expectations-from-the-union-budget-2016-17/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/heath-care-my-expectations-from-the-union-budget-2016-17/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Manipulation: Leapfrogging Dangerously Into Clinical Trial Domain</title>
		<link>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain</link>
		<comments>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/#comments</comments>
		<pubDate>Mon, 03 Aug 2015 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[700]]></category>
		<category><![CDATA[Aurobindo]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jugaad]]></category>
		<category><![CDATA[Leapfrog]]></category>
		<category><![CDATA[Leapfrogging]]></category>
		<category><![CDATA[lifesciences]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[Malpractice]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[quest]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigmarole]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6908</guid>
		<description><![CDATA[Over the last several years, repeated allegations of gross data manipulative practices, detected by global drug regulatory agencies, such as USFDA and MHRA, have shaken the Indian pharma exporting companies hard. This has been hurting the overall business performance of &#8230; <a href="http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
